VectivBio AG is a clinical-stage biotechnology company focused on transformational therapeutics for rare diseases, spun out from Therachon in 2019. The company draws on the expertise of its founders to build a portfolio of rare disease medicines while advancing apraglutide for Short Bowel Syndrome.

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
  • Number of employees in Switzerland
Key business